- Home
- HURA vs INMB Comparison
HURA vs INMB Comparison
Compare HURA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- INMB
- Stock Information
- Founded
- HURA 2009
- INMB 2015
- Country
- HURA United States
- INMB United States
- Employees
- HURA N/A
- INMB N/A
- Industry
- HURA
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- HURA
- INMB Health Care
- Exchange
- HURA Nasdaq
- INMB Nasdaq
- Market Cap
- HURA 246.9M
- INMB 203.5M
- IPO Year
- HURA N/A
- INMB 2019
- Fundamental
- Price
- HURA $3.33
- INMB $8.59
- Analyst Decision
- HURA Strong Buy
- INMB Strong Buy
- Analyst Count
- HURA 1
- INMB 2
- Target Price
- HURA $11.00
- INMB $21.50
- AVG Volume (30 Days)
- HURA 216.5K
- INMB 462.2K
- Earning Date
- HURA 03-04-2025
- INMB 03-27-2025
- Dividend Yield
- HURA N/A
- INMB N/A
- EPS Growth
- HURA N/A
- INMB N/A
- EPS
- HURA N/A
- INMB N/A
- Revenue
- HURA N/A
- INMB $42,000.00
- Revenue This Year
- HURA N/A
- INMB N/A
- Revenue Next Year
- HURA N/A
- INMB N/A
- P/E Ratio
- HURA N/A
- INMB N/A
- Revenue Growth
- HURA N/A
- INMB N/A
- 52 Week Low
- HURA $2.84
- INMB $4.32
- 52 Week High
- HURA $14.60
- INMB $13.52
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- INMB 51.55
- Support Level
- HURA N/A
- INMB $8.90
- Resistance Level
- HURA N/A
- INMB $9.58
- Average True Range (ATR)
- HURA 0.00
- INMB 0.93
- MACD
- HURA 0.00
- INMB -0.20
- Stochastic Oscillator
- HURA 0.00
- INMB 16.23
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.